Cellid, Co., Ltd.

KOSDAQ 299660.KQ

Cellid, Co., Ltd. Gross Profit Margin for the year ending December 31, 2023

Cellid, Co., Ltd. Gross Profit Margin is NA for the year ending December 31, 2023. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Cellid, Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was -495.54%, a -226.69% change year over year.
Cellid, Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was -151.68%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

KOSDAQ: 299660.KQ

Cellid, Co., Ltd.

CEO	Yuil Kang Chang
IPO Date	Feb. 19, 2019
Location	South Korea
Headquarters	Building 142, Korea Seoul National University
Employees	64
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.

Key trends

Past 5 years